CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Jason A. Amello

Profile

Jason A. Amello

Chief Financial Officer (Principal Financial Officer), TScan Therapeutics, Inc.

Leaving, effective November 2026. First published here October 28, 2026; built from records as of October 28, 2026.

Jason A. Amello is leaving the chief financial officer seat at TScan Therapeutics, Inc.: the company's filing of September 30, 2026 gives November 2026 as the effective date.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
TScan Therapeutics, Inc. (TCRX)
Biological Products, (No Diagnostic Substances)
Chief Financial Officer (Principal Financial Officer)Leaving, effective November 20262

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. November 2026takes effect

    TScan Therapeutics, Inc. reported the departure of Jason A. Amello from the chief financial officer seat, effective November 2026.

    Amello would cease to serve as the Company’s Chief Financial Officer and Chrystal Louis, M.D., MPH, would cease to serve as the Company’s Chief Medical Officer.

    [2] Filing by TScan Therapeutics, Inc., filed with the SEC on September 30, 2026. Read the filing. The record at CFO Tribune.

  2. March 4, 202610-K filed

    Jason A. Amello signed the annual report of TScan Therapeutics, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer), filed March 4, 2026.

    /s/ Jason A. Amello Jason A. Amello Chief Financial Officer (Principal Financial Officer)

    [1] Annual report on Form 10-K by TScan Therapeutics, Inc., filed with the SEC on March 4, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, TScan Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 4, 2026. sec.gov; record.
  2. Current report filed with the SEC, TScan Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 30, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Jason A. Amello wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.